Yohei Takahashi

1
Article
This action will reload the page results.
Journal article

Effectiveness, biomarker transition, and safety of 48-week tralokinumab treatment for atopic dermatitis: real-world analyses stratified by age groups (15-17, 18-64, and ≥ 65 years)

In European Journal of Dermatology (2026/2 Vol. 36)